Anti-CYTC/ CST3/ ARMD11 monoclonal antibody

Anti-CYTC/ CST3/ ARMD11 antibody for FACS & in-vivo assay

Target products collectionGo to CST3/CST3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0338-Ab-1/ GM-Tg-hg-MP0338-Ab-2Anti-Human CST3 monoclonal antibodyHuman
GM-Tg-rg-MP0338-Ab-1/ GM-Tg-rg-MP0338-Ab-2Anti-Rat CST3 monoclonal antibodyRat
GM-Tg-mg-MP0338-Ab-1/ GM-Tg-mg-MP0338-Ab-2Anti-Mouse CST3 monoclonal antibodyMouse
GM-Tg-cynog-MP0338-Ab-1/ GM-Tg-cynog-MP0338-Ab-2Anti-Cynomolgus/ Rhesus macaque CST3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0338-Ab-1/ GM-Tg-felg-MP0338-Ab-2Anti-Feline CST3 monoclonal antibodyFeline
GM-Tg-cang-MP0338-Ab-1/ GM-Tg-cang-MP0338-Ab-2Anti-Canine CST3 monoclonal antibodyCanine
GM-Tg-bovg-MP0338-Ab-1/ GM-Tg-bovg-MP0338-Ab-2Anti-Bovine CST3 monoclonal antibodyBovine
GM-Tg-equg-MP0338-Ab-1/ GM-Tg-equg-MP0338-Ab-2Anti-Equine CST3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0338-Ab-1/ GM-Tg-hg-MP0338-Ab-2; GM-Tg-rg-MP0338-Ab-1/ GM-Tg-rg-MP0338-Ab-2;
GM-Tg-mg-MP0338-Ab-1/ GM-Tg-mg-MP0338-Ab-2; GM-Tg-cynog-MP0338-Ab-1/ GM-Tg-cynog-MP0338-Ab-2;
GM-Tg-felg-MP0338-Ab-1/ GM-Tg-felg-MP0338-Ab-2; GM-Tg-cang-MP0338-Ab-1/ GM-Tg-cang-MP0338-Ab-2;
GM-Tg-bovg-MP0338-Ab-1/ GM-Tg-bovg-MP0338-Ab-2; GM-Tg-equg-MP0338-Ab-1/ GM-Tg-equg-MP0338-Ab-2
Products NameAnti-CST3 monoclonal antibody
Formatmab
Target NameCST3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Diagnostic target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CST3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CYTC/ CST3/ ARMD11 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMLP002896human CST3 Lentivirus particle
    ORF Viral VectorpGMLP002896human CST3 Lentivirus plasmid
    ORF Viral VectorpGMLV000153mouse Cst3 Lentivirus plasmid
    ORF Viral VectorvGMLV000153mouse Cst3 Lentivirus particle


    Target information

    Target IDGM-MP0338
    Target NameCST3
    Gene ID1471,13010,574313,100058494
    Gene Symbol and SynonymsARMD11,CST3,CysC,HEL-S-2
    Uniprot AccessionP01034,O19092
    Uniprot Entry NameCYTC_HUMAN,CYTC_MACMU
    Protein Sub-locationTransmembrane Protein
    CategoryDiagnostics Biomarker
    Diseasecarcinoma, Diabetic Nephropathy, Nephrotoxicity, Sjogren's syndrome salivary, Perinatal necrotizing enterocolitis, Acute kidney failure, Asphyxia neonatorum, Dent disease, Metabolic syndrome, Nephropathy induced by heavy metals, Renal fibrosis
    Gene EnsemblENSG00000101439
    Target ClassificationN/A

    The target: CST3, gene name: CST3, also named as ARMD11, HEL-S-2. The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. The cystatin locus on chromosome 20 contains the majority of the type 2 cystatin genes and pseudogenes. This gene is located in the cystatin locus and encodes the most abundant extracellular inhibitor of cysteine proteases, which is found in high concentrations in biological fluids and is expressed in virtually all organs of the body. A mutation in this gene has been associated with amyloid angiopathy. Expression of this protein in vascular wall smooth muscle cells is severely reduced in both atherosclerotic and aneurysmal aortic lesions, establishing its role in vascular disease. In addition, this protein has been shown to have an antimicrobial function, inhibiting the replication of herpes simplex virus. Alternative splicing results in multiple transcript variants encoding a single protein. [provided by RefSeq, Nov 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.